Diagnostic value of Ca 19-9 antigen in patients with chronic pancreatitis or pancreatic adenocarcinoma: Effects of complications;Valeur diagnostique de l'antigene serique Ca 19-9 au cours de la pancreatite chronique et de l'adenocarcinome pancreatique: Influence de leurs complications

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 2, 1998, Pages 152-159

  Nouts, Aline ^a   Lévy, Philippe ^a,b   Voitot, Hélène ^a   Bernades, Pierre ^a  

^a BEAUJON HOSPITAL   (France)

^b INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Ca 19 9; Choletasis; Chronic pancreatitis; Diabetes; Neoplasm; Pancreas; Pancreatic carcinoma; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHOLESTASIS; CHRONIC PANCREATITIS; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PANCREAS DISEASE; PANCREATITIS; ADENOCARCINOMA; BLOOD; CHRONIC DISEASE; IMMUNOLOGY; MIDDLE AGED; PANCREAS TUMOR; REFERENCE VALUE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CHOLESTASIS; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; REFERENCE VALUES;

EID: 0031993395     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Farini R, Fabris C, Bonvicin P, Piccoli A, Del Favero G, Venturini R et al. Ca 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis. Eur J Cancer Clin Oncol 1985 ;21:429-32.
2. Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF et al. Comparison of the sensitivity and specificity of the Ca 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986;90:343-9.
3. Venot J, Vincent D, Gainant A, Descottes B, Cessot F, Beck C. L'antigène carbohydrate Ca 19-9: intérêt au cours de la pathologie pancréatique. Gastroenterol Clin Biol 1986;10:208-10.
4. Safi F, Beger HG, Bittnet R, Büchler M, Krautzberger. Ca 19-9 and pancreatic adenocarcinoma. Cancer 1986;57:779-83.
5. Paganuzzi M, Onetto M, Marroni P, Barone D, Conio M, Aste H et al. Ca 19-9 and Ca 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988;61:2100-8.
6. Safi F, Roscher R, Beger HG. Tumor markers in pancreatic cancer. Sensitivity and specificity of Ca 19-9. Hepatogastroenterology 1989;36:419-23.
7. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, Ca 19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110:704-9.
8. Steinberg WM. The clinical utility of the Ca 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5.
9. Delvillano BC, Brennan S, Brock P, Bacher C, Lin V, MacClure M et al. Radio-immunometric assay for a monoclonal antibody defined tumor marker Ca 19-9. Clin Chem 1983;29:549-52.
10. Gupta MK, Arciaga R, Bocci L, Tubbs R, Bukowski R, Deodhar D. Measurement of a monoclonal-antibody-defined antigen (Ca 19-9) in the sera of patients with malignant and nonmalignant diseases. Cancer 1985;56:277-83.
11. Harmenberg U, Wahren B, Wiechel KL. Tumor markers carbohydrate antigens Ca 19-9 and Ca 50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract. Cancer Res 1988;48:1985-8.
12. Welfare M, Tanner A. Ca 19-9 estimation in the assessment of pancreatic or biliary tract malignancy: what is the most efficient threshold value ? Eur J Gastroenterol Hepatol 1991;3:539-43.
13. Piantino P, Andriulli A, Gindro T, Pecchio F, Masoero G, Cavallini G et al. Ca 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Am J Gastroenterol 1986;81:436-9.
14. Malesci A, Tommasini MA, Bonato C, Bocchia P, Bersani M, Zerbi A et al. Determination of Ca 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987;92:60-7.
15. Sarner M. Pancreatitis. Definition and classifiaction. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. The pancreas. Biology, pathobiology, and disease. New York: Raven, 1993:581-91.
16. Von Rosen A, Linder S, Harmenberg U. Serum levels of Ca 19-9 and Ca 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas 1993;8;160-5.
17. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen Ca 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987;47:5501-3.
18. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979;5:957-72.
19. Rougier P, Ychou M, Bidart JM, Bellet D. Utilité des marqueurs tumoraux en hépato-gastroentérologie. Gastroenterol Clin Biol 1989;13:l-5.
20. Yoshikawa T, Nishida K, Tanigawa M, Futumoto K, Kondo M. Carbohydrate antigenic determinant Ca 19-9 and other tumor marker in gastrointestinal malignancies. Digestion 1985;31:67-76.
21. Sakamoto K, Haga Y, Yoshimura R, Egami H, Yokoyama Y, Akagi M. Comparative effectiveness of the tumor diagnostics, Ca 19-9, Ca 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut 1987;28:323-9.
22. Hyöty M, Hyöty H, Aaran RK, Airo I, Nordback I. Tumors antigens Ca 195 and Ca 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma. Eur J Surg 1992;158:173-9.
23. Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H. Gastrointestinal cancer-associated antigen in immunoperoxydase assay. Cancer Res 1982;42:4820-3.
24. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker Ca 19-9 in acute cholangitis. Dig Dis Sci 1988;33:1223-5.
25. Deugnier YM, Rabot A-F, Guyader D, Moirand R, Turlin B, Boucher E et al. Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemachromatosis. Gut 1994;35:1107-11.
26. Mc Farlane IG. Hepatic clearance of serum glycoproteins. Clin Sci 1983;64:127-35.
27. Nakamura N, Aoji O, Yoshikawa T, Mori K, Kajiyama S, Kitagawa Y, et al. Elevated serum Ca 19-9 levels in poorly controled diabetic patients. Jpn J Med 1986;25:278-80.
28. Aoki Y, Yanagisawa Y, Ohfusa H, Kawa S, Oguchi H, Furuta S. Elevation of serum Ca 19-9 in parallel with HbA1c in a diabetic female with the Lewis(a + b-) blood group. Diabetes Res Clin Pract 1991;13:77-82.
29. Petit JM, Vaillant G, Olsson NO, Guignier F, Collignon S, Verges B, et al. Elevated serum Ca 19-9 levels in poorly controlled diabetic patients. Relationship with Lewis blood group. Gastroenterol Clin Biol 1994;18:17-20.
30. Kennedy L, Baynes JW. Non-enzymatic glycosylaton and the chronic complications of diabetes: an overview. Diabetologia 1984;26:93-8.
31. Collazos J, Genolla J, Ruibal A. Ca 19-9 in non-neoplastic liver diseases. A clinical and laboratory study. Clin Chim Acta 1992; 210:145-51.
32. Del Favero G, Fabris C, Panucci A, Basso D, Plebani M, Baccaglini U et al. Carbohydrate antigen Ca 19-9 (Ca 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Bull Cancer 1986; 73:251-5.
33. Pearce S, Thornes H, Carr D, Tanner A. Diagnostic pitfall; interpretation of Ca 19-9 concentrations in the presence of hepatic dysfunction. Gut 1994;35:707-8.